GRO Biosciences

About:

GRO Biosciences is a biotechnology company that develops a protein therapeutics technology to improve treatments across multiple diseases.

Website: https://www.grobio.com

Twitter/X: gro_bio

Top Investors: Alumni Ventures, National Science Foundation, Digitalis Ventures, Redmile Group, Atlas Venture

Description:

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.

Total Funding Amount:

$92.6M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2016-01-01

Founders:

Andrew Ellington, Benjamin Stranges, Christopher Gregg, Daniel J. Mandell, Marc Lajoie, Ross Thyer

Number of Employees:

11-50

Last Funding Date:

2024-07-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai